Title:
MESENCHYMAL STEM CELL EXPRESSING TRAIL AND CD, AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2017/135800
Kind Code:
A1
Abstract:
The present invention relates to: a recombinant lentivirus vector comprising a gene encoding a TRAIL protein and a CD protein; and a cell that is transfected with the lentivirus produced by using the vector. A host cell transfected with the recombinant lentivirus of the present invention maintains a high cell proliferation rate and overexpresses a TRAIL protein and a CD protein. Thus, a mesenchymal stem cell transfected with the lentivirus may be usefully employed as a cell therapeutic agent.
More Like This:
Inventors:
SUNG YOUNG CHUL (KR)
LEE SOON MIN (KR)
KIM HEY-YON (KR)
LEE SOON MIN (KR)
KIM HEY-YON (KR)
Application Number:
PCT/KR2017/001308
Publication Date:
August 10, 2017
Filing Date:
February 06, 2017
Export Citation:
Assignee:
SLBIGEN INC (KR)
International Classes:
C12N15/86; A61K35/28; A61K48/00; C07K14/47; C12N5/0775; C12N9/10; C12N9/78
Foreign References:
| KR20130089214A | 2013-08-09 | |||
| US5763223A | 1998-06-09 | |||
| US6596533B1 | 2003-07-22 |
Other References:
WENGER ET AL.: "Specific Resistance upon Lentiviral TRAIL Transfer by Intracellular Retention of TRAIL Receptors", CELL DEATH & DIFFERENTIATION, vol. 13, 2006, pages 1740 - 1751, XP055406264
WEI ET AL.: "Cytosine Deaminase/5-fluorocytosine Gene Therapy and Apo2L/TRAIL Cooperate to Kill TRAIL-resistant Tumor Cells", CANCER GENE THERAPY, vol. 14, 2007, pages 640 - 651, XP055406265
WEI ET AL.: "Cytosine Deaminase/5-fluorocytosine Gene Therapy and Apo2L/TRAIL Cooperate to Kill TRAIL-resistant Tumor Cells", CANCER GENE THERAPY, vol. 14, 2007, pages 640 - 651, XP055406265
Attorney, Agent or Firm:
FIRSTLAW P.C. (KR)
Download PDF: